Littérature scientifique sur le sujet « Optimisation hit-To-Lead »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Optimisation hit-To-Lead ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Optimisation hit-To-Lead"
Padalino, Gilda, Nelly El-Sakkary, Lawrence J. Liu, Chenxi Liu, Danielle S. G. Harte, Rachel E. Barnes, Edward Sayers et al. « Anti-schistosomal activities of quinoxaline-containing compounds : From hit identification to lead optimisation ». European Journal of Medicinal Chemistry 226 (décembre 2021) : 113823. http://dx.doi.org/10.1016/j.ejmech.2021.113823.
Texte intégralEl Bakali, Jamal, Lucie Maingot, Julie Dumont, Helene Host, Akila Hocine, Nicolas Cousaert, Sandrine Dassonneville, Florence Leroux, Benoit Deprez et Rebecca Deprez-Poulain. « Novel selective inhibitors of neutral endopeptidase : discovery by screening and hit-to-lead optimisation ». MedChemComm 3, no 4 (2012) : 469. http://dx.doi.org/10.1039/c2md00287f.
Texte intégralZaidi, Norburhanuddin Johari, Adib Afandi Abdullah, Choon Han Heh, Chun-Hung Lin, Rozana Othman et Abdullah Al Hadi Ahmad Fuaad. « Hit-to-Lead Short Peptides against Dengue Type 2 Envelope Protein : Computational and Experimental Investigations ». Molecules 27, no 10 (18 mai 2022) : 3233. http://dx.doi.org/10.3390/molecules27103233.
Texte intégralBobrovs, Raitis, Jekaterina Bolsakova, Jhon Alexander Rodriguez Buitrago, Larisa Varaceva, Marija Skvorcova, Iveta Kanepe, Anastasija Rudnickiha, Emilio Parisini et Aigars Jirgensons. « Structure-based identification of salicylic acid derivatives as malarial threonyl tRNA-synthetase inhibitors ». PLOS ONE 19, no 4 (1 avril 2024) : e0296995. http://dx.doi.org/10.1371/journal.pone.0296995.
Texte intégralMostarda, Serena, Tugçe Gür Maz, Alessandro Piccinno, Bruno Cerra et Erden Banoglu. « Optimisation by Design of Experiment of Benzimidazol-2-One Synthesis under Flow Conditions ». Molecules 24, no 13 (3 juillet 2019) : 2447. http://dx.doi.org/10.3390/molecules24132447.
Texte intégralTaki, Aya C., Joseph J. Byrne, Tao Wang, Brad E. Sleebs, Nghi Nguyen, Ross S. Hall, Pasi K. Korhonen et al. « High-Throughput Phenotypic Assay to Screen for Anthelmintic Activity on Haemonchus contortus ». Pharmaceuticals 14, no 7 (26 juin 2021) : 616. http://dx.doi.org/10.3390/ph14070616.
Texte intégralOsborne, James, Stanislava Panova, Magdalini Rapti, Tatsuya Urushima et Harren Jhoti. « Fragments : where are we now ? » Biochemical Society Transactions 48, no 1 (27 janvier 2020) : 271–80. http://dx.doi.org/10.1042/bst20190694.
Texte intégralKandil, Sahar B., Samuel R. Jones, Sonia Smith, Stephen E. Hiscox et Andrew D. Westwell. « Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer ». Molecules 25, no 15 (31 juillet 2020) : 3488. http://dx.doi.org/10.3390/molecules25153488.
Texte intégralRichardson, Caroline J., Mladen Vincovic, Charlotte East, Nicola Wallis, George Ward et Andrew Woodhead. « Abstract A142 : Fragment based discovery of inhibitors of the eIF4E:eIF4G interaction ». Molecular Cancer Therapeutics 22, no 12_Supplement (1 décembre 2023) : A142. http://dx.doi.org/10.1158/1535-7163.targ-23-a142.
Texte intégralWorkman, Paul. « Abstract IA014 : From targeted phenotypic screen to NXP800 : A clinical stage activator of the integrated stress response for the treatment of ARID1A-mutated ovarian carcinoma ». Molecular Cancer Therapeutics 22, no 12_Supplement (1 décembre 2023) : IA014. http://dx.doi.org/10.1158/1535-7163.targ-23-ia014.
Texte intégralThèses sur le sujet "Optimisation hit-To-Lead"
Quevedo, Camilo E. « Design and synthesis of Quinazolinone-based libraries for inhibitation of Kinase activity and hit-to-lead optimisation of Wnt pathway inhibitors ». Thesis, Institute of Cancer Research (University Of London), 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.510367.
Texte intégralBorzakian, Sibyline. « Identification et développement chimique d'inducteurs de protéines immunorégulatrices (SLPI et IL-10) à visée thérapeutique ». Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASF012.
Texte intégralThe work carried out during this thesis has been divided into three distincts parts, all relating to the developpement of compounds for therapeutic use. The first part of this manuscript is devoted to the identification of inducers of Secretory Leucocyte Protease Inhibitor (SLPI), a protein mainly produced by immune and epithelial cells, with numerous promising biological properties. A phenotypic screening was conducted using two academic chemical libraries, leading to the identification of 5 hits able of inducing SLPI production by B cells. This work paved the way for potential therapeutic applications of these compounds, particularly in the development of antibiotic or anti-inflammatory treatments. The second part of this manuscript is dedicated to identifying a pharmacophore for inducers of Interleukin-10 (IL-10), a cytokine produced by immune cells, whose main role is the regulation of immunity. Prior to this thesis, a phenotypic screening was conducted to identifiy inducers of IL-10 production by B cells for use in cell therapy to reduce symptoms of multiple sclerosis. This thesis work involved hit-to-lead optimization of the most promising compound to identify a pharmacophore for IL-10 inducers through the establishment of robust structure-activity relationships. During this phase, 240 analogs were synthetized. Finally, the third part of this manuscript focuses on the development of a photochemical synthesis methology for accessing original heterocylic compounds. This methology, requiring neither heating nor metallic catalysts, aligns with the development of greener chemistry
Voitovich, Iuliia. « Les inhibiteurs d'interaction protéine-protéine, une stratégie innovante en cancérologie ». Thesis, Aix-Marseille, 2018. http://www.theses.fr/2018AIXM0701.
Texte intégralBET-proteins, acting as epigenetic readers, play an essential role in cancer development. To date, numerous potent inhibitors disrupting BET functions have been discovered, including several of them that are undergoing clinical trials for the treatment of different types of cancer. The common drawback limiting their use in clinical practice is an inability to distinguish between BET-members that may cause side effects and resistances. The selective targeting of individual BET and the discrimination between BD1 and BD2 present an opportunity to achieve more selective transcriptional effect. A midthroughput screening of previously designed chemical library allowed identification of two molecules with unique profiles of selectivity that have never been observed. An undertaken structure-based program revealed a minimum scaffolds necessary for binding. Taking together with resolved X-Ray structures it allowed the development of more potent and selective BET inhibitors by DOTS (diversity oriented target focused synthesis) strategy, combining virtual screening and diversity oriented library design. This optimization led to a potent inhibitor with up to 100-fold improvement of affinity to the target and up to 300-fold selectivity toward BD1. Dose-response downregulation of c-Myc levels in low micromolar range in cell assays allowed the validation of the identified molecule as a chemical probe. Further comprehensive in vitro and in vivo evaluations of this compound will enable elucidating the biological role of each bromodomain and a validation of the interest toward the development of selective inhibitors in clinic
Chapitres de livres sur le sujet "Optimisation hit-To-Lead"
Narjes, Frank, Garry Pairaudeau et Dušan Petrović. « Lead Generation ». Dans The Handbook of Medicinal Chemistry, 682–719. The Royal Society of Chemistry, 2023. http://dx.doi.org/10.1039/9781788018982-00682.
Texte intégralWard, Simon E., et Andrew M. Davis. « Lead Optimisation : What You Should Know ! » Dans The Handbook of Medicinal Chemistry, 720–68. The Royal Society of Chemistry, 2023. http://dx.doi.org/10.1039/9781788018982-00720.
Texte intégral